Glucagon-Like Peptide-1 Protects Against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic Mice

Visual Abstract

• Publication year

  2023

• Venue

  JACC: Basic to Translational Science

• Publication date

  2023-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jacbts.2023.01.005PMID 37719430PMCID 10504404
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Suppression of angiotensin II-activated NOX4/NADPH oxidase and mitochondrial dysfunction by preserving glucagon-like peptide-1 attenuates myocardial fibrosis and hypertension.

  2022cited by this paper
• Liraglutide inhibits AngII-induced cardiac fibroblast proliferation and ECM deposition through regulating miR-21/PTEN/PI3K pathway

  2022cited by this paper
• Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials.

  2022cited by this paper
• Guidelines for assessment of cardiac electrophysiology and arrhythmias in small animals

  2022cited by this paper
• Impaired regulation of heart rate and sinoatrial node function by the parasympathetic nervous system in type 2 diabetic mice

  2021cited by this paper
• Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages

  2021cited by this paper
• New aspects of endocrine control of atrial fibrillation and possibilities for clinical translation

  2021cited by this paper
• Comparison of the effect of glucose-lowering agents on the risk of atrial fibrillation: A network meta-analysis.

  2021cited by this paper
• NLRP3 inflammasome is a key driver of Obesity-Induced atrial arrhythmias.

  2021cited by this paper
• The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction

  2020cited by this paper
• Loss of insulin signaling may contribute to atrial fibrillation and atrial electrical remodeling in type 1 diabetes

  2020cited by this paper
• Atrial remodeling and atrial fibrillation in acquired forms of cardiovascular disease

  2020influential reference
• Epidemiology of Atrial Fibrillation in the 21st Century

  2020cited by this paper
• Electrical and structural remodeling contribute to atrial fibrillation in type 2 diabetic db/db mice.

  2020influential reference
• The Association Between Diabetes Mellitus and Atrial Fibrillation: Clinical and Mechanistic Insights

  2019cited by this paper
• NPR-C (Natriuretic Peptide Receptor-C) Modulates the Progression of Angiotensin II–Mediated Atrial Fibrillation and Atrial Remodeling in Mice

  2019cited by this paper
• Conduction in cardiac tissue. Historical reflections

  2019cited by this paper
• Heterogeneity of the action potential duration is required for sustained atrial fibrillation.

  2019cited by this paper
• Liraglutide suppresses atrial electrophysiological changes

  2019cited by this paper
• Prevalence and predictors of atrial arrhythmias in patients with sinus node dysfunction and atrial pacing

  2018cited by this paper
• GLP-1 Receptor Expression Within the Human Heart

  2018cited by this paper
• Comparative Study of Liraglutide and Insulin Glargine on Glycemic Control and Pancreatic β-Cell Function in db/db Mice

  2018cited by this paper
• Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti‐diabetic therapies

  2018cited by this paper
• Distinct patterns of atrial electrical and structural remodeling in angiotensin II mediated atrial fibrillation.

  2018cited by this paper
• Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

  2017cited by this paper
• Molecular and Cellular Mechanisms of Atrial Fibrosis in Atrial Fibrillation.

  2017influential reference
• Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes

  2017cited by this paper
• Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

  2016cited by this paper
• A simple practice guide for dose conversion between animals and human

  2016cited by this paper
• Ion Channels in the Heart.

  2015cited by this paper
• Liraglutide

  2015cited by this paper
• The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms.

  2014influential reference
• Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.

  2014cited by this paper
• Cardiovascular actions of incretin-based therapies.

  2014influential reference
• Cellular and Molecular Electrophysiology of Atrial Fibrillation Initiation, Maintenance, and Progression

  2014cited by this paper
• Sinus node dysfunction in atrial fibrillation patients: the evidence of regional atrial substrate remodelling.

  2013cited by this paper
• Cardiovascular biology of the incretin system.

  2012cited by this paper
• Liraglutide

  2010cited by this paper
• [Epidemiology of atrial fibrillation].

  2010cited by this paper
• Recipes for creating animal models of diabetic cardiovascular disease.

  2007cited by this paper
• Continuous stimulation of human glucagon-like peptide-1 (7–36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes

  2007cited by this paper
• Molecular physiology of cardiac repolarization.

  2005cited by this paper
• Dispersion of ventricular repolarization and refractory period.

  2001cited by this paper
• Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study.

  1994cited by this paper

• Impairment of mitochondrial quality control exacerbates diabetes-related atrial fibrillation by cGAS-STING signaling pathway and cardiomyocyte-macrophage crosstalk

  2026cites this paper
• Research on epicardial adipose tissue as a metabolic therapeutic target in AF: focus on GLP-1 receptor agonists

  2026cites this paper
• Emerging Regulatory Mechanisms in Sinoatrial Node Automaticity

  2026cites this paper
• Potential Antiarrhythmic Mechanisms of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs)

  2026cites this paper
• Non-antiarrhythmic pharmacotherapy in cardio-renal-metabolic disease and incident atrial fibrillation: a trial meta-analysis.

  2026cites this paper
• Molecular Mechanisms of Atrial Fibrillation Recurrence After Successful Catheter Ablation

  2025cites this paper
• Obesity and Atrial Fibrillation: A Comprehensive Review

  2025cites this paper
• GLP1R upregulation in mitral regurgitation observed at a single nucleus level.

  2025cites this paper
• Risk Factors for New-Onset Atrial Fibrillation in Thai Adults with Hypertension

  2025cites this paper
• Emerging Treatments for Obesity: the Role of GLP1 Receptor Agonists on Stroke

  2025cites this paper
• Clinical effectiveness of tirzepatide for patients with atrial fibrillation and type 2 diabetes: A retrospective cohort study.

  2025cites this paper
• Association of glucagon-like peptide-1 receptor agonists with atrial fibrillation, cardiac arrest, and ventricular fibrillation: Casual evidence from a drug target Mendelian randomization

  2025cites this paper
• Impact of GLP-1 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis

  2025cites this paper
• SGLT2 inhibitors are associated with a reduced incidence of atrial fibrillation in type 2 diabetes mellitus

  2025cites this paper
• Association of Glucagon-Like Peptide-1 Receptor Agonist with Incident Atrial Fibrillation

  2025cites this paper
• Potential Therapeutic Benefits of Glucagon-Like-Peptide-1 Agonists and Atrial Fibrillation.

  2025cites this paper
• Atrial Fibrillation in Diabetes: Pathogenesis and Targeted Rhythm Control Strategies

  2025cites this paper
• Factors Associated with New-Onset Atrial Fibrillation in Thai Adults with Hypertension.

  2025cites this paper
• Exploring the Cardiopulmonary Effects of Tirzepatide in Atrial Fibrillation and Comorbid Chronic Obstructive Pulmonary Disease.

  2025cites this paper
• Effect of Semaglutide on Atrial Arrhythmias Recurrence Following Ablation for Atrial Fibrillation: A Prospective Study.

  2025cites this paper
• Arrhythmia-Induced Cardiomyopathy in Atrial Fibrillation: Pathogenesis, Diagnosis, and Treatment

  2025cites this paper
• Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: a meta-analysis of randomized controlled trials.

  2025cites this paper
• Understanding the Diseased Atria.

  2025cites this paper
• Integrated Management of Persistent Atrial Fibrillation

  2025cites this paper
• IL-1β enhances susceptibility to atrial fibrillation in mice by acting through resident macrophages and promoting caspase-1 expression

  2025cites this paper
• Proarrhythmic Lipid Inflammatory Mediators: Mechanisms in Obesity Arrhythmias

  2025cites this paper
• Effects of Glucagon-Like Peptide-1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation.

  2024cites this paper
• Semaglutide for the prevention of atrial fibrillation: A systematic review and meta-analysis.

  2024cites this paper
• New insights into the effects of glucagon-like peptide-1 on heart rate and sinoatrial node function.

  2024cites this paper
• Human Gut Microbiota in Cardiovascular Disease.

  2024cites this paper
• Incretin‐based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future

  2024cites this paper
• Effects of Glucagon-Like Peptide 1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation: A Systematic Review and Meta-analysis

  2024cites this paper
• Stellate ganglion, inflammation, and arrhythmias: a new perspective on neuroimmune regulation

  2024cites this paper
• Amiodarone Therapy: Updated Practical Insights

  2024cites this paper
• Atrial Fibrillation Management with Guideline-Directed Medical Therapy and Comorbidity Treatment in Heart Failure Patients.

  2024cites this paper
• Atrial Fibrillation Nomenclature, Definitions and Mechanisms:Position Paper from the International Working Group of the Signal Summit.

  2024cites this paper
• Albiglutide and atrial fibrillation in patients with type 2 diabetes and established cardiovascular disease - insights from the Harmony Outcomes trial.

  2024cites this paper
• Repurposing Metformin for the Treatment of Atrial Fibrillation: Current Insights

  2024cites this paper
• [Cardio- and neuroprotective role of glucagon-like receptor-1 agonists in reducing the incidence of ischemic stroke accompanying type 2 diabetes].

  2024cites this paper
• Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications

  2024cites this paper
• Obesity and Atrial Fibrillation: Therapeutic Perspective for GLP-1 Analogs

  2024cites this paper
• GLP-1 Receptor Agonists, the Holy Grail Preventing Atrial Fibrillation in Patients With T2D?

  2023cites this paper
• Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges

  2023cites this paper